Equity Capital Markets

Nektar Therapeutics

02/26
s
Piper Sandler served as bookrunner for Nektar Therapeutics on its follow-on offering
Sub-Type
Follow-On Offering
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
w
Flowco
Confidentially Marketed Follow-On Offering
Lead Bookrunner
e
CytomX Therapeutics Inc.
Follow-On Offering
Active Bookrunner
$538.0 Million
s
MiniMed Inc.
Initial Public Offering
Passive Bookrunner
$413.7 Million
d
Nurix
ATM Program Common Stock
Sole Placement Agent
3
Medline Industries
Follow-On
Passive Bookrunner
$50.0 Million
e
Bridgewater Bancshares
ATM Program Common Stock
Sole Placement Agent
$400.0 Million
s
Generate Biomedicines, Inc.
Initial Public Offering
Passive Bookrunner
s
Zura Bio
Confidentially Marketed Follow-On Offering
Active Bookrunner
$170.0 Million
g
Innovex Downhole Solutions, Inc
Follow-On Offering
Active Bookrunner
$201.3 Million
l
Select Water Solutions
Following-On Offering
Active Bookrunner
$500.0 Million
e
Terreno
ATM Program Common Stock
Joint Placement Agent
f
OKYO Pharma
Confidentially Marketed Follow-On Offering
Financial Advisor
s
Nektar Therapeutics
Follow-On Offering
Active Bookrunner
$94.5 Million
t
Lexicon Pharmaceuticals, Inc.
CMFO and PIPE
Active Bookrunner
$250.0 Million
d
Rithm Capital
Preferred Stock
Joint Bookrunner
o
BioAge Labs
Follow-On Offering
Active Bookrunner

© 2026 Piper Sandler Companies. Since 1895. All rights reserved.